Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Increase in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 17,114 shares, an increase of ∞ from the April 30th total of 0 shares. Based on an average trading volume of 28,945 shares, the short-interest ratio is currently 0.6 days. Approximately 0.0% of the shares of the stock are sold short.

Inhibitor Therapeutics Price Performance

Shares of OTCMKTS:INTI remained flat at $0.09 during trading on Monday. The firm has a market capitalization of $14.69 million, a price-to-earnings ratio of -8.50 and a beta of -0.60. The firm has a 50-day moving average price of $0.09 and a 200-day moving average price of $0.07. Inhibitor Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.12.

Inhibitor Therapeutics (OTCMKTS:INTI) last issued its quarterly earnings data on Friday, May 15th. The company reported $999.00 earnings per share (EPS) for the quarter.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.